Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 9/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399999 | 1.00 | AHCY (0.73) | AHCYADORA2BP2RY1ADORA3 | |
| SCHEMBL19503479 | 1.00 | AHCY (0.73) | AHCYADORA2BP2RY1ADORA3 | |
| SCHEMBL29319924 | 0.89 | AHCY (0.57) | AHCYADORA2BP2RY1ADORA3 | |
| SCHEMBL22399995 | 0.89 | AHCY (0.57) | AHCYADORA2BP2RY1ADORA3 | |
| SCHEMBL16290177 | 0.88 | AHCY (0.56) | AHCYADORA2BP2RY1 | |
| SCHEMBL12330956 | 0.88 | AHCY (0.56) | AHCYADORA2BP2RY1 | |
| SCHEMBL4147869 | 0.87 | AHCY (0.68) | AHCYADORA2BADORA3 | |
| SCHEMBL10673149 | 0.85 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL10673142 | 0.85 | AHCY (1.00) | AHCYADORA2B | |
| Phosphoric Acid SCHEMBL8862399 | 0.83 | AHCY (0.62) | AHCYADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019157317-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2017185061-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |